Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein

被引:155
作者
Zhang, SZ
Yang, XN
Coburn, RA
Morris, ME
机构
[1] SUNY Buffalo, Univ Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[2] SUNY Buffalo, Univ Buffalo, Dept Chem, Buffalo, NY 14260 USA
关键词
breast cancer resistance protein; flavonoids; structure activity relationships; quantitative structure activity relationships; mitoxantrone transport; membrane transport;
D O I
10.1016/j.bcp.2005.05.017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Breast cancer resistance protein (BCRP) is a newly identified ABC transporter, which plays an important role in drug disposition and represents an additional mechanism for the development of MDR. Flavonoids, a major class of natural compounds widely present in foods and herbal products, have been shown to be BCRP inhibitors. The objective of the present study was to elucidate the SAR and derive a QSAR model for flavonoid-BCRP interaction. The EC50 values for increasing mitoxantrone accumulation in MCF-7 MX 100 cells for 25 flavonoids, from five flavonoid subclasses, were determined in this study or obtained from our previous publication [Zhang S, Yang X, Morris ME. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004;21(7):1263-73], and ranged from 0.07 +/- 0.02 mu M to 183 +/- 21.7 mu M. We found that the presence of a 2,3-double bond in ring C, ring B attached at position 2, hydroxylation at position 5, lack of hydroxylation at position 3 and hydrophobic substitution at positions 6, 7, 8 or 4, are important structural properties important for potent flavonoid-BCRP interaction. These structural requirements are similar but not identical to those for potent flavonoid-NBD2 (P-glycoprotein) interaction, indicating that inhibition of BCR-P by flavonoids may involve, in part, the binding of flavonoids with the NBD of BCRP. In addition, a QSAR model consisting three structural descriptors was constructed, and both internally and externally validated, suggesting the model could be used to quantitatively predict BCRP inhibition activity of flavonoids. These findings should be useful for predicting BCRP inhibition activity of other untested flavonoids and for guiding the synthesis of potent BCRP inhibitors for potential clinical application. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:627 / 639
页数:13
相关论文
共 41 条
[21]   Expression of multidrug resistance-related transporters in human breast carcinoma [J].
Kanzaki, A ;
Toi, M ;
Nakayama, K ;
Bando, H ;
Mutoh, M ;
Uchida, T ;
Fukumoto, M ;
Takebayashi, Y .
JAPANESE JOURNAL OF CANCER RESEARCH, 2001, 92 (04) :452-458
[22]   Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 [J].
Kruijtzer, CMF ;
Beijnen, JH ;
Rosing, H ;
Huinink, WWT ;
Schot, M ;
Jewell, RC ;
Paul, EM ;
Schellens, JHM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) :2943-2950
[23]   DIETARY-EFFECTS ON BREAST-CANCER RISK IN SINGAPORE [J].
LEE, HP ;
GOURLEY, L ;
DUFFY, SW ;
ESTEVE, J ;
LEE, J ;
DAY, NE .
LANCET, 1991, 337 (8751) :1197-1200
[24]   From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance [J].
Litman, T ;
Druley, TE ;
Stein, WD ;
Bates, SE .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2001, 58 (07) :931-959
[25]  
Maliepaard M, 2001, CANCER RES, V61, P3458
[26]  
Middleton E, 2000, PHARMACOL REV, V52, P673
[27]  
Miyake K, 1999, CANCER RES, V59, P8
[28]   A Randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients [J].
Nikander, E ;
Kilkkinen, A ;
Metsä-Heikkilä, M ;
Adlercreutz, H ;
Pietinen, P ;
Tiitinen, A ;
Ylikorkala, O .
OBSTETRICS AND GYNECOLOGY, 2003, 101 (06) :1213-1220
[29]   Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women [J].
Potter, SM ;
Baum, JA ;
Teng, HY ;
Stillman, RJ ;
Shay, NF ;
Erdman, JW .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1998, 68 (06) :1375S-1379S
[30]  
Rabindran SK, 1998, CANCER RES, V58, P5850